

IN THE SPECIFICATION:

A second substitute specification is being filed as a separate paper on even date herewith.

IN THE CLAIMS:

Please amend the claims as follows:

6. (Three-times amended) Synthetic polypeptide as claimed in claim 2, corresponding to one of the following formulas:

SEQ ID NO: 10 (X)-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R<sub>13</sub>)-(Y)

SEQ ID NO: 11 (X)-Tyr-Tyr-R<sub>3</sub>-Pro-R<sub>4</sub>-Asp-R<sub>5</sub>-Tyr-R<sub>6</sub>-(Asn-Gln)-(Y)

SEQ ID NO: 12 (X)-Tyr-Tyr-R<sub>3</sub>-Pro-R<sub>4</sub>-Asp-R<sub>5</sub>-Tyr-R<sub>6</sub>-(Asn-Gln)-Z-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R<sub>13</sub>)-(Y)

where X and Y are arbitrary amino-acid sequences, Z is a conventional spacer such as Gly-Gly, R<sub>3</sub> = Arg or Lys, R<sub>4</sub> = Met, Val or Ala, R<sub>5</sub> = Gln, Glu or Arg, R<sub>6</sub> = Ser or Asn and R<sub>13</sub> = Met or Val, and where the sequence zones in parentheses need not necessarily be present.

13. (Three-times amended) A pharmaceutical preparation, a diagnostic means or vaccine as claimed in claim 1, characterized in that the PrP<sup>Sc</sup> - binding substance it contains is a recombinantly produced rbPrP of the formula of SEQ ID NO: 13 or in the form of genus-specific deviations thereof.